# Olema Oncology, Inc.

**OLMA**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001750284

# None

**No letter**

6 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $533.4M |
| **Warnings** | dilution, short runway, thin data<br>not computable: degenerate inputs, fortress balance sheet |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 16, 2026<br>242 days before the rescan; latest periodic filing 10-Q received Nov 10, 2026 |
| **Last close** | $7.52<br>2026-11-12; market equity $658.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 16, 2026*

Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 70.5** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (3.2%) | (6.6%) | | 70.5 | 800 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 29.0** | | | | | |
| Twelve-month failure probability | 0.15% | 0.08% | 59.8 | 247 | 2026-09-30 |
| Altman Z double-prime | 8.96 | (0.35) | 10.5 | 744 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 9.95x | 2.95x | 16.8 | 826 | 2025-12-31 |
| **Growth and financing, sleeve percentile 39.6** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | |
| *four consecutive annual FCF observations are required; found 3* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *required facts have no common fiscal period end* | | | | | |
| Asset growth, three years | 35.2% | 2.2% | 13.1 | 694 | 2025-12-31 |
| Net share issuance, one year | 27.5% | 2.5% | 66.1 | 627 | 2026-03-11 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 27.5% |
| Short runway | cash runway is 3.2 months |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-12 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (3.7%) | (1.9%) | 49 |
| Distance from 52-week high | (79.0%) | (30.8%) | 9 |
| EBIT to enterprise value | not computable | (1.9%) | |
| Free cash flow yield | (15.9%) | (1.0%) | 28 |
| Book value to price | 0.56 | 0.28 | 72 |
| Sales to price | not computable | 0.29 | |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | (0.21) | (0.19) | 49 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $47.5M |
| Operating cash flow, four quarters | -$177.3M |
| Months of runway | 3.2 |
| Days since last periodic filing | 3 (10-Q received Nov 10, 2026) |
| Median daily dollar volume, 63 sessions | $9.4M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$162.5M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$146.7M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 3 | assets | us-gaap:Assets | $533.4M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 4 | assets | us-gaap:Assets | $451.0M | 2024-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 5 | current assets | us-gaap:AssetsCurrent | $515.5M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $51.8M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$597.6M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$178.7M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 9 | book equity | us-gaap:StockholdersEquity | $478.6M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 10 | liabilities | us-gaap:Liabilities | $54.9M | 2025-12-31 | 2026-03-16 | 10-K | 26-107169 |
| 11 | assets | us-gaap:Assets | $276.9M | 2023-12-31 | 2025-03-18 | 10-K | 25-041204 |
| 12 | assets | us-gaap:Assets | $215.6M | 2022-12-31 | 2024-03-11 | 10-K | 24-029281 |
| 13 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 87,156,961 | 2026-03-11 | 2026-03-16 | 10-K | 26-107169 |
| 14 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 68,333,065 | 2025-03-13 | 2025-03-18 | 10-K | 25-041204 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.